- $5.78m
- $0.93m
- $5.44m
- 21
- 34
- 15
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2 | ||
| Price to Tang. Book | 2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -489.97% | ||
| Return on Equity | -385.53% | ||
| Operating Margin | -288.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5 | 6.9 | 8.04 | 1.95 | 5.44 | n/a | n/a | 13.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
Directors
- N. Anthony Coles NEC (61)
- Richard Peters PRE (59)
- Michael Wyzga CFO (32)
- Ajay Verma EVP (59)
- Paulash Mohsen OTH (47)
- Brigitte Robertson OTH (58)
- Richard Heyman LED (63)
- Patricia Allen IND (59)
- David Arkowitz IND (59)
- Kimberlee Drapkin IND (53)
- Jeffery Kelly IND (60)
- Cecil Pickett IND (76)
- Lynne Zydowsky IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 13th, 2006
- Public Since
- February 11th, 2016
- No. of Shareholders
- 270
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 10,962,460
- Address
- 7683 Se 27Th Street, Suite 481, MERCER ISLAND, 98040
- Web
- https://kinetabio.com/
- Phone
- +1 2063780400
- Contact
- Lee Roth
- Auditors
- Marcum LLP
Upcoming Events for KA
Kineta Inc Annual Shareholders Meeting
Q2 2024 Kineta Inc Earnings Release
Similar to KA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Kineta share price?
As of Today at 19:12 UTC, shares in Kineta are trading at $0.53. This share price information is delayed by 15 minutes.
How has the Kineta share price performed this year?
Shares in Kineta last closed at $0.53 and the price had moved by -86.99% over the past 365 days. In terms of relative price strength the Kineta share price has underperformed the S&P500 Index by -89.17% over the past year.
What are the analyst and broker recommendations for Kineta?
The overall consensus recommendation for Kineta is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kineta dividend yield?
Kineta does not currently pay a dividend.
Does Kineta pay a dividend?
Kineta does not currently pay a dividend.
When does Kineta next pay dividends?
Kineta does not currently pay a dividend.
How do I buy Kineta shares?
To buy shares in Kineta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kineta?
As of the previous close price of $0.53, shares in Kineta had a market capitalisation of $5.78m.
Where are Kineta shares listed?
Here are the trading details for Kineta:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KA
What kind of share is Kineta?
Based on an overall assessment of its quality, value and momentum Kineta is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kineta share price forecast for 2024?
The analyst consensus target price for shares in Kineta is $13.50. That is 2461.67% above the last closing price of $0.53.
Analysts covering Kineta currently have a consensus Earnings Per Share (EPS) forecast of -$1.41 for the next financial year.
What is the trend in the Kineta share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kineta. Over the past six months, its share price has underperformed the S&P500 Index by -87.75%.
As of the last closing price of $0.53, shares in Kineta were trading -78.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kineta PE Ratio?
The Kineta PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kineta?
Kineta's management team is headed by:
- N. Anthony Coles - NEC
- Richard Peters - PRE
- Michael Wyzga - CFO
- Ajay Verma - EVP
- Paulash Mohsen - OTH
- Brigitte Robertson - OTH
- Richard Heyman - LED
- Patricia Allen - IND
- David Arkowitz - IND
- Kimberlee Drapkin - IND
- Jeffery Kelly - IND
- Cecil Pickett - IND
- Lynne Zydowsky - IND